

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number
WO 2005/010029 A1

(51) International Patent Classification⁷: C07K 5/078,
A61K 38/05, A61P 31/14

Zhe [US/US]; 67 Westwoods Blvd., Hockessin, DE 19707
(US).

(21) International Application Number:
PCT/US2004/015802

(74) Agent: FERRONE, Jason, D.; Enanta Pharmaceuticals,
Inc, 500 Arsenal Street, Watertown, MA 02472 (US).

(22) International Filing Date: 19 May 2004 (19.05.2004)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

English

(26) Publication Language: English

English

(30) Priority Data:
10/613,206 3 July 2003 (03.07.2003) US

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): ENANTA
PHARMACEUTICALS, INC. [US/US]; Patent Dept.,
500 Arsenal Street, Watertown, MA 02472 (US).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): WU, Frank, X., H.
[CN/US]; 5 Aspen Road, Shrewsbury, MA 01545 (US).
NAKAJIMA, Suanne [CA/US]; 225 Walden Street, Apt.
E, Cambridge, MA 02140 (US). OR, Yat, Sun [US/US];
169 Fayette Street, Watertown, MA 02472 (US). LU,
Zhi-Hui [CN/US]; 4 Brentwood Drive, Shrewsbury, MA
01545 (US). SUN, Ying [CN/US]; 220 School Street, ST 6,
Waltham, MA 02451 (US). MIAO, Zhenwei [CN/US]; 1
B Thunder Hill Road, Medway, MA 02053 (US). WANG,

(54) Title: AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS



(57) Abstract: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

WO 2005/010029 A1

AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

TECHNICAL FIELD

5

The present invention relates to novel macrocycles having activity against hepatitis C virus (HCV) and useful in the treatment of HCV infections. More particularly, the invention relates to macrocyclic compounds, compositions containing such compounds and methods for using the same, as well as processes 10 for making such compounds.

BACKGROUND OF THE INVENTION

HCV is the principal cause of non-A, non-B hepatitis and is an increasingly 15 severe public health problem both in the developed and developing world. It is estimated that the virus infects over 200 million people worldwide, surpassing the number of individuals infected with the human immunodeficiency virus (HIV) by nearly five fold. HCV infected patients, due to the high percentage of individuals inflicted with chronic infections, are at an elevated risk of developing cirrhosis of the 20 liver, subsequent hepatocellular carcinoma and terminal liver disease. HCV is the most prevalent cause of hepatocellular cancer and cause of patients requiring liver transplantations in the western world.

There are considerable barriers to the development of anti-HCV therapeutics, which include, but are not limited to, the persistence of the virus, the genetic diversity 25 of the virus during replication in the host, the high incident rate of the virus developing drug-resistant mutants, and the lack of reproducible infectious culture systems and small-animal models for HCV replication and pathogenesis. In a majority of cases, given the mild course of the infection and the complex biology of the liver, careful consideration must be given to antiviral drugs, which are likely to 30 have significant side effects.

Only two approved therapies for HCV infection are currently available. The original treatment regimen generally involves a 3-12 month course of intravenous interferon- α (IFN- α), while a new approved second-generation treatment involves co-

treatment with IFN- α and the general antiviral nucleoside mimics like ribavirin. Both of these treatments suffer from interferon related side effects as well as low efficacy against HCV infections. There exists a need for the development of effective antiviral agents for treatment of HCV infection due to the poor tolerability and disappointing

5 efficacy of existing therapies.

In a patient population where the majority of individuals are chronically infected and asymptomatic and the prognoses are unknown, an effective drug must possess significantly fewer side effects than the currently available treatments. The hepatitis C non-structural protein-3 (NS3) is a proteolytic enzyme required for 10 processing of the viral polyprotein and consequently viral replication. Despite the huge number of viral variants associated with HCV infection, the active site of the NS3 protease remains highly conserved thus making its inhibition an attractive mode of intervention. Recent success in the treatment of HIV with protease inhibitors supports the concept that the inhibition of NS3 is a key target in the battle against 15 HCV.

HCV is a flaviridae type RNA virus. The HCV genome is enveloped and contains a single strand RNA molecule composed of circa 9600 base pairs. It encodes a polypeptide comprised of approximately 3010 amino acids.

The HCV polyprotein is processed by viral and host peptidase into 10 discreet 20 peptides which serve a variety of functions. There are three structural proteins, C, E1 and E2. The P7 protein is of unknown function and is comprised of a highly variable sequence. There are six non-structural proteins. NS2 is a zinc-dependent metalloproteinase that functions in conjunction with a portion of the NS3 protein. NS3 incorporates two catalytic functions (separate from its association with NS2): a 25 serine protease at the N-terminal end, which requires NS4A as a cofactor, and an ATP-ase-dependent helicase function at the carboxyl terminus. NS4A is a tightly associated but non-covalent cofactor of the serine protease.

The NS3.4A protease is responsible for cleaving four sites on the viral 30 polyprotein. The NS3-NS4A cleavage is autocatalytic, occurring in cis. The remaining three hydrolyses, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B all occur in trans. NS3 is a serine protease which is structurally classified as a chymotrypsin-like protease. While the NS serine protease possesses proteolytic activity by itself, the HCV protease enzyme is not an efficient enzyme in terms of catalyzing polyprotein


cleavage. It has been shown that a central hydrophobic region of the NS4A protein is required for this enhancement. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficacy at all of the sites.

5 A general strategy for the development of antiviral agents is to inactivate virally encoded enzymes, including NS3, that are essential for the replication of the virus. Current efforts directed toward the discovery of NS3 protease inhibitors were reviewed by S. Tan, A. Pause, Y. Shi, N. Sonenberg, *Hepatitis C Therapeutics: Current Status and Emerging Strategies*, *Nature Rev. Drug Discov.*, 1, 867-881
 10 (2002). More relevant patent disclosures describing the synthesis of HCV protease inhibitors are: WO 00/59929 (2000); WO 99/07733 (1999); WO 00/09543 (2000); WO 99/50230 (1999); US5861297 (1999).

Summary of the Invention

15 The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or
 20 pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

In one embodiment of the present invention there are disclosed compounds represented by Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:



wherein

A is selected from:

(a) hydrogen;

(b) $-(C=O)-O-R_1$, where R_1 is selected from:

1. hydrogen,
2. C_1-C_6 alkyl,
3. C_3-C_{12} cycloalkyl,
4. substituted C_3-C_{12} cycloalkyl,
5. aryl,
6. substituted aryl,
7. heteroaryl,
8. substituted heteroaryl,
9. heterocycloalkyl,
10. substituted heterocycloalkyl, or
11. $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

(c) $-(C=O)-R_2$, where R_2 is selected from:

1. R_1 , as previously defined,
2. alkylamino,
3. dialkyl amino,
4. arylamino, or
5. diarylamino;

(d) $-C(=O)-NH-R_2$, where R_2 is as previously defined;

(e) $-C(=S)-NH-R_2$, where R_2 is as previously defined;

(f) $-S(O)_2-R_2$, where R_2 is as previously defined;

B is hydrogen or C_1-C_6 alkyl;

G is

- (a) $-OH$;
- (b) $-O-(C_1-C_{12}$ alkyl);
- (c) $-NH-R_2$, where R_2 is as previously defined;
- (d) $-NHS(O)_2-R_1$, where R_1 is as previously defined;
- (e) $-(C=O)-R_2$, where R_2 is as previously defined;
- (f) $-(C=O)-O-R_1$, where R_1 is as previously defined; or

(g) $-(C=O)-NH-R_2$, where R_2 is as previously defined;

M is absent or selected from:

(a) $-O-$;

(b) $-S-$;

5 (c) $-NH-$; or

(d) $-NR_1-$, wherein R_1 is as previously defined;

Q is selected from:

(a) aryl;

(b) substituted aryl;

10 (c) heteroaryl;

(d) substituted heteroaryl;

(e) heterocycloalkyl; or

(f) substituted heterocycloalkyl;

j = 0, 1, 2, 3, or 4;

15 n = 0, 1, or 2; and

s = 0, 1, or 2.

Detailed Description of the Invention

A first embodiment of the invention is a compound represented by Formula I


20 as described above, or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient.

A second embodiment of the invention is a compound represented by

Formula II as described above, or a pharmaceutically acceptable salt, ester or

25 prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Representative subgenera of the invention include, but are not limited to:




A compound of formula I, wherein M is absent and Q is

30 wherein X and Y are each independently selected from:

- a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 5 b) $-C_2-C_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-C_2-C_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 10 d) aryl;
- e) substituted aryl;
- 15 f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, X and Y are taken together with the carbons to which
 20 they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;




A compound of formula I, wherein M is absent and Q is

25 wherein Y is selected from:

- a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-C_2-C_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from

halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

- 5 c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- 10 g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;




A compound of formula I, wherein M is absent and Q is

15 wherein X, Y, and Z are each independently selected from:

- a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 20 b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- 25 g) substituted heteroaryl;

- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, X and Y or Y and Z are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;




A compound of formula I, wherein M is absent and Q is

wherein W, X, Y, and Z are each independently selected from:

- 10 a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 20 d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- 25 g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, W and X, X and Y, or Y and Z are taken together with the carbons to which they are attached to for a cyclic moiety selected from:

- 30 aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;




A compound of formula I, wherein M is absent and Q is

wherein X, Y, and Z are each independently selected from:

- a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-C_2-C_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-C_2-C_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, Y and Z are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;



A compound of formula I, wherein M is $-O-$ and Q is

wherein

L is M, where M is as previously defined;

X, Y, and Z are each independently selected from:


- a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

10

15

20

or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;



25 A compound of formula I, wherein M is $-\text{O}-$ and Q is

wherein

L is M, where M is as previously defined;

X, Y, and Z are each independently selected from:

30


- a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from

halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

- 5 b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 10 d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- 15 g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl; or

20 A compound of formula I, wherein M is $-\text{O}-$ and Q is



wherein

L is M, where M is as previously defined;

25 X, Y, and Z are each independently selected from:

- j) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- k) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from

halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

1) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from

5 halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

m) aryl;

n) substituted aryl;

o) heteroaryl;

10 p) substituted heteroaryl;

q) heterocycloalkyl; or

r) substituted heterocycloalkyl;

or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl.

Representative compounds of the invention include, but are not limited to, the following compounds:

20 Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-\text{O}-$, Q = hydrogen, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-\text{O}-$, Q = $-\text{S}(\text{O})_2\text{CH}_3$, and j = n = s = 1;

25 Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-\text{O}-$, Q = 2-thiophenyl-quinolin-3-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = $-\text{O}-$, Q = 2-thiophenyl-quinolin-3-yl, and j = n = s = 1;

30 Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M is absent, Q = 4,5-diphenyltriazolyl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4,5-di-thiophenyltriazol-2-yl, and j = n = s = 1;

5 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(thiophen-3-yl)-5-(p-methoxyphenyl)triazol-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(n-butyl)-5-phenyl triazol-2-yl, and j = n = s = 1;

10 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3-methoxyphenyl)tetrazolyl, and j = n = s = 1;

15 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(4-pyridyl)tetrazolyl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3,4-dichlorophenyl)tetrazolyl, and j = n = s = 1;

20 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3-bromo-4-methoxy-phenyl)tetrazolyl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(4-fluoro-phenyl)-6-phenyl-1H-pyridazin-3-on-2-yl, and j = n = s = 1;

25 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 6-phenyl-5-piperidin-1-yl-1H-pyridazin-3-on-2-yl, and j = n = s = 1;

30 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-phenyl-quinolin-4-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-thiazolyl-quinolin-4-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-thiophenyl-quinolin-4-yl, and j = n = s = 1;

5 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-(thiophen-2-yl)-1H-quinoxalin-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 6-Methoxy-3-(thiophen-2-yl)-1H-quinoxalin-2-yl, and j = n = s = 1;

10 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-[2-(thiophen-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1;

15 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 6-Methoxy-3-[2-(thiophen-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-[2-(pyridin-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1; or

20 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-methoxy-3-[2-(pyridin-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1.

According to an alternate embodiment, the pharmaceutical compositions of the present invention may further contain other anti-HCV agents. Examples of anti-HCV agents include, but are not limited to, α -interferon, β -interferon, ribavirin, and amantadine.

According to an additional alternate embodiment, the pharmaceutical compositions of the present invention may further contain other HCV protease inhibitors.

According to yet another alternate embodiment, the pharmaceutical compositions of the present invention may further comprise inhibitor(s) of other

targets in the HCV life cycle, including, but not limited to, helicase, polymerase, metalloprotease, and internal ribosome entry site (IRES).

According to a further embodiment, the present invention includes methods of
5 treating hepatitis C infections in a subject in need of such treatment by administering
to said subject an anti-HCV virally effective amount of the pharmaceutical
compositions of the present invention.

In addition, the present invention contemplated methods of making any
10 compound delineated herein via any synthetic means delineated herein.

Definitions

Listed below are definitions of various terms used to describe this invention.
15 These definitions apply to the terms as they are used throughout this specification
and claims, unless otherwise limited in specific instances, either individually or as
part of a larger group.

The terms "C₁-C₃ alkyl," "C₁-C₆ alkyl," or "C₁-C₁₂ alkyl," as used herein, refer
20 to saturated, straight- or branched-chain hydrocarbon radicals containing between
one and three, one and twelve, or one and six carbon atoms, respectively. Examples
of C₁-C₃ alkyl radicals include methyl, ethyl, propyl and isopropyl radicals; examples
of C₁-C₆ alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl,
n-butyl, *tert*-butyl, neopentyl and n-hexyl radicals; and examples of C₁-C₁₂ alkyl
25 radicals include, but are not limited to, ethyl, propyl, isopropyl, n-hexyl, octyl, decyl,
dodecyl radicals.

The term "substituted alkyl," as used herein, refers to a "C₂-C₁₂ alkyl" or "C₁-
C₆ alkyl" group as previously defined, substituted by independent replacement or
30 one, two, or three of the hydrogen atoms thereon with substituents including, but not
limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally
substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-
alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH -C₁-C₁₂-alkyl,
-NH -C₂-C₁₂-alkenyl, -NH -C₂-C₁₂-alkenyl, -NH -C₃-C₁₂-cycloalkyl, -NH -aryl, -NH -

heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -diaryl amino, -diheteroaryl amino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)aryl, -NHC(NH)heteroaryl, -NHC(NH)heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)aryl, -S(O)heteroaryl, -S(O)heterocycloalkyl, -SO₂NH₂, -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₂-C₁₂-alkenyl, -C₂-C₁₂-alkenyl, -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-heteroaryl, -SO₂NH-heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂aryl, -NHSO₂heteroaryl, -NHSO₂heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -

methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The terms "C₂-C₁₂ alkenyl" or "C₂-C₆ alkenyl," as used herein, denote a

5 monovalent group derived from a hydrocarbon moiety containing from two to twelve or two to six carbon atoms having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like.

10 The term "substituted alkenyl," as used herein, refers to a "C₂-C₁₂ alkenyl" or "C₂-C₆ alkenyl" group as previously defined, substituted by independent replacement or one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with

15 halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₁₂-alkenyl, -NH-C₂-C₁₂-alkenyl, -NH-C₃-C₁₂-cycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-

20 C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -

25 OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -

30 NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-

C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH- C₁-C₁₂-alkyl, - NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-
5 heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, - NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, - C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, - S(O)-C₂-C₁₂-alkenyl, -
10 S(O)-C₂-C₁₂-alkenyl, - S(O)-C₃-C₁₂-cycloalkyl, - S(O)-aryl, - S(O)-heteroaryl, - S(O)-heterocycloalkyl -SO₂NH₂, -SO₂NH- C₁-C₁₂-alkyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₃-C₁₂-cycloalkyl, -SO₂NH- aryl, -SO₂NH- heteroaryl, - SO₂NH- heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, - NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -
15 NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, - heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, - methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

20 The terms "C₂-C₁₂ alkynyl" or "C₂-C₆ alkynyl," as used herein, denote a monovalent group derived from a hydrocarbon moiety containing from two to twelve or two to six carbon atoms having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, and the like.

25 The term "substituted alkynyl," as used herein, refers to a "C₂-C₁₂ alkynyl" or "C₂-C₆ alkynyl" group as previously defined, substituted by independent replacement or one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl
30 optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH -C₁-C₁₂-alkyl, -NH -C₂-C₁₂-alkenyl, -NH -C₂-C₁₂-alkenyl, -NH -C₃-C₁₂-cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocycloalkyl, -dialkylamino, -diarylamino, - diheteroarylamino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-

cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)- C₁-C₁₂-alkyl, -C(O)- C₂-C₁₂-alkenyl, -C(O)- C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH- C₁-C₁₂-alkyl, -CONH- C₂-C₁₂-alkenyl, -CONH- C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH- heteroaryl, -CONH-heterocycloalkyl, -OCO₂- C₁-C₁₂-alkyl, -OCO₂- C₂-C₁₂-alkenyl, -OCO₂- C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH- C₁-C₁₂-alkyl, -OCONH- C₂-C₁₂-alkenyl, -OCONH- C₂-C₁₂-alkenyl, -OCONH- C₃-C₁₂-cycloalkyl, -OCONH- aryl, -OCONH- heteroaryl, -OCONH- heterocycloalkyl, -NHC(O)- C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂- C₁-C₁₂-alkyl, -NHCO₂- C₂-C₁₂-alkenyl, -NHCO₂- C₂-C₁₂-alkenyl, -NHCO₂- C₃-C₁₂-cycloalkyl, -NHCO₂- aryl, -NHCO₂- heteroaryl, -NHCO₂- heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH- C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(S)NH₂, NHC(S)NH- C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH- C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH- C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl -SO₂NH₂, -SO₂NH- C₁-C₁₂-alkyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₃-C₁₂-cycloalkyl, -SO₂NH- aryl, -SO₂NH- heteroaryl, -SO₂NH- heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The term "C₁-C₆ alkoxy," as used herein, refers to a C₁-C₆ alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom. Examples of C₁-C₆-alkoxy include, but are not limited to, methoxy, ethoxy, propoxy,

5 isopropoxy, *n*-butoxy, *tert*-butoxy, neopentoxy and *n*-hexoxy.

The terms "halo" and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.

10 The term "aryl," as used herein, refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.

15 The term "substituted aryl," as used herein, refers to an aryl group, as previously defined, substituted by independent replacement of one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH -C₁-C₁₂-alkyl, -NH -C₂-C₁₂-alkenyl, -NH -C₂-C₁₂-alkenyl, -NH -C₃-C₁₂-cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)- C₁-C₁₂-alkyl, -C(O)- C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH- C₁-C₁₂-alkyl, -CONH- C₂-C₁₂-alkenyl, -CONH- C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂- C₁-C₁₂-alkyl, -OCO₂- C₂-C₁₂-alkenyl, -OCO₂- C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH- C₁-C₁₂-alkyl, -OCONH- C₂-C₁₂-alkenyl, -OCONH- C₂-C₁₂-alkenyl, -OCONH- C₃-C₁₂-cycloalkyl, -OCONH- aryl, -OCONH- heteroaryl, -OCONH- heterocycloalkyl, -NHC(O)- C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂- C₁-C₁₂-alkyl, -NHCO₂- C₂-C₁₂-alkenyl, -NHCO₂- C₃-C₁₂-cycloalkyl, -NHCO₂- aryl, -

NHCO₂- heteroaryl, -NHCO₂- heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH- C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH- C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH- C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl -SO₂NH₂, -SO₂NH- C₁-C₁₂-alkyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₃-C₁₂-cycloalkyl, -SO₂NH- aryl, -SO₂NH- heteroaryl, -SO₂NH- heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The term "arylalkyl," as used herein, refers to a C₁-C₃ alkyl or C₁-C₆ alkyl residue attached to an aryl ring. Examples include, but are not limited to, benzyl, phenethyl and the like.

The term "substituted arylalkyl," as used herein, refers to an arylalkyl group, as previously defined, substituted by independent replacement or one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH -C₁-C₁₂-alkyl, -NH -C₂-C₁₂-alkenyl, -NH -C₂-C₁₂-alkenyl, -NH -C₃-C₁₂-cycloalkyl, -NH -aryl, -NH -

heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -diaryl amino, -diheteroaryl amino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)aryl, -NHC(NH)heteroaryl, -NHC(NH)heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl, -SO₂NH₂, -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₂-C₁₂-alkenyl, -C₂-C₁₂-alkenyl, -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-heteroaryl, -SO₂NH-heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -

methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The term "heteroaryl," as used herein, refers to a mono-, bi-, or tri-cyclic aromatic radical or ring having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, 5 imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like.

The term "substituted heteroaryl," as used herein, refers to a heteroaryl group 15 as previously defined, substituted by independent replacement of one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₁₂-alkenyl, -NH-C₂-C₁₂-alkenyl, -NH-C₃-C₁₂-cycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -diaryl amino, -diheteroaryl amino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -

NHCO₂- heteroaryl, -NHCO₂- heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH- C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH- C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH- C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl -SO₂NH₂, -SO₂NH- C₁-C₁₂-alkyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₃-C₁₂-cycloalkyl, -SO₂NH- aryl, -SO₂NH- heteroaryl, -SO₂NH- heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The term "C₃-C₁₂-cycloalkyl," as used herein, denotes a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.

The term "substituted C₃-C₁₂-cycloalkyl," as used herein, refers to a C₃-C₁₂-cycloalkyl group as previously defined, substituted by independent replacement of one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH -C₁-C₁₂-alkyl,

-NH -C₂-C₁₂-alkenyl, -NH -C₂-C₁₂-alkenyl, -NH -C₃-C₁₂-cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocycloalkyl, -dialkylamino, -diaryl amino, -diheteroaryl amino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-

5 C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-

10 heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-

15 C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-

20 C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-

25 C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-

30 heterocycloalkyl -SO₂NH₂, -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-heteroaryl, -SO₂NH-heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -

heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

5 The term "heterocycloalkyl," as used herein, refers to a non-aromatic 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms 10 may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, and (v) any of the above rings may be fused to a benzene ring. Representative heterocycloalkyl groups include, but are not limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and 15 tetrahydrofuryl.

The term "substituted heterocycloalkyl," as used herein, refers to a heterocycloalkyl group, as previously defined, substituted by independent replacement or one, two, or three of the hydrogen atoms thereon with substituents 20 including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₁₂-alkenyl, -NH-C₂-C₁₂-alkenyl, -NH-C₃-C₁₂-cycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -25 diarylamino, -diheteroarylamino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-30 aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-

C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl, -SO₂NH₂, -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-heteroaryl, -SO₂NH-heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The term "heteroarylalkyl," as used herein, refers to a C₁-C₃ alkyl or C₁-C₆ alkyl residue residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.

30

The term "substituted heteroarylalkyl," as used herein, refers to a heteroarylalkyl group, as previously defined, substituted by independent replacement of one, two, or three of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -C₁-C₁₂-alkyl

optionally substituted with halogen, C₂-C₁₂-alkenyl optionally substituted with halogen, -C₂-C₁₂-alkynyl optionally substituted with halogen, -NH₂, protected amino, -NH -C₁-C₁₂-alkyl, -NH -C₂-C₁₂-alkenyl, -NH -C₂-C₁₂-alkenyl, -NH -C₃-C₁₂-cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocycloalkyl, -dialkylamino, -diaryl amino, -

5 diheteroaryl amino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl, -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)- C₁-C₁₂-alkyl, -C(O)- C₂-C₁₂-alkenyl, -C(O)- C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH- C₁-C₁₂-alkyl, -CONH- C₂-C₁₂-alkenyl, -CONH- C₂-C₁₂-alkenyl, -CONH- C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-
10 heteroaryl, -CONH-heterocycloalkyl, -OCO₂- C₁-C₁₂-alkyl, -OCO₂- C₂-C₁₂-alkenyl, -OCO₂- C₂-C₁₂-alkenyl, -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH- C₁-C₁₂-alkyl, -OCONH- C₂-C₁₂-alkenyl, -OCONH- C₂-C₁₂-alkenyl, -OCONH- C₃-C₁₂-cycloalkyl, -OCONH- aryl, -OCONH-
15 heteroaryl, -OCONH- heterocycloalkyl, -NHC(O)- C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO₂- C₁-C₁₂-alkyl, -NHCO₂- C₂-C₁₂-alkenyl, -NHCO₂- C₂-C₁₂-alkenyl, -NHCO₂- C₃-C₁₂-cycloalkyl, -NHCO₂- aryl, -NHCO₂- heteroaryl, -NHCO₂- heterocycloalkyl, -NHC(O)NH₂, NHC(O)NH- C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-
20 C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, NHC(S)NH- C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂, NHC(NH)NH- C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-
25 C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₃-C₁₂-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-
30 heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl -SO₂NH₂, -SO₂NH- C₁-C₁₂-alkyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₂-C₁₂-alkenyl, -SO₂NH- C₃-C₁₂-cycloalkyl, -SO₂NH- aryl, -SO₂NH- heteroaryl, -SO₂NH- heterocycloalkyl, -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-

C₂-C₁₂-alkenyl, -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl, -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C₃-C₁₂-cycloalkyl, -methoxymethoxy, -methoxyethoxy, -SH, -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-

5 C₁₂-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

The term "C₁-C₃-alkyl-amino," as used herein, refers to one or two C₁-C₃-alkyl groups, as previously defined, attached to the parent molecular moiety through a nitrogen atom. Examples of C₁-C₃-alkyl-amino include, but are not limited to,

10 methylamino, dimethylamino, ethylamino, diethylamino, and propylamino.

The term "alkylamino" refers to a group having the structure -NH(C₁-C₁₂ alkyl) where C₁-C₁₂ alkyl is as previously defined.

15 The term "dialkylamino" refers to a group having the structure -N(C₁-C₁₂ alkyl)(C₁-C₁₂ alkyl), where C₁-C₁₂ alkyl is as previously defined. Examples of dialkylamino are, but not limited to, dimethylamino, diethylamino, methylethylamino, piperidino, and the like.

20 The term "alkoxycarbonyl" represents an ester group, i.e., an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like.

25 The term "carboxaldehyde," as used herein, refers to a group of formula -CHO.

The term "carboxy," as used herein, refers to a group of formula -COOH.

30 The term "carboxamide," as used herein, refers to a group of formula -C(O)NH(C₁-C₁₂ alkyl) or -C(O)N(C₁-C₁₂ alkyl) (C₁-C₁₂ alkyl), -C(O)NH₂, and the like.

The term "hydroxy protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group against

undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed.

Hydroxy protecting groups as known in the art are described generally in T.H. Greene and P.G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley &

5 Sons, New York (1999). Examples of hydroxy protecting groups include, but are not limited to, methylthiomethyl, *tert*-butyl-dimethylsilyl, *tert*-butyldiphenylsilyl, acyl substituted with an aromatic group and the like.

The term "protected hydroxy," as used herein, refers to a hydroxy group

10 protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.

The term "amino protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired

15 reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino protecting groups as known in the art are described generally in T.H. Greene and P.G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, *t*-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.

The term "protected amino," as used herein, refers to an amino group protected with an amino protecting group as defined above.

25 The term "aprotic solvent," as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor. Examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such compounds are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred

temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick *et al.*, Vol. II, in the Techniques of Chemistry Series, John Wiley &

5 Sons, NY, 1986.

The term "protogenic organic solvent," as used herein, refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like. Such solvents are well known
10 to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in
15 specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick *et al.*, Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

Combinations of substituents and variables envisioned by this invention are
20 only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

25 The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident
30 to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock,

Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for

5 Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

The term "subject" as used herein refers to an animal. Preferably the animal is a mammal. More preferably the mammal is a human. A subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.

10

The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system),

15 increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic 20 number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

The compounds described herein contain one or more asymmetric centers 25 and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers may be prepared from their respective optically active precursors by the procedures 30 described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). When

the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers or cis- and trans- isomers. Likewise, all tautomeric forms are also intended to be included. The 5 configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as *trans* may be *cis*, *trans*, or a mixture of the two in any proportion.

10

As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable 15 benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, *et al.* describes pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 66: 1-19 (1977). The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or 20 separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable include, but are not limited to, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid 25 or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, 30 glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, *p*-toluenesulfonate, undecanoate, valerate salts, and the like.

Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate,

5 phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

As used herein, the compounds of this invention, including the compounds of formulae described herein, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention.

15 When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The 20 additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

25

Antiviral Activity

According to the methods of treatment of the present invention, viral infections are treated or prevented in a subject such as a human or lower mammal by 30 administering to the subject a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result. The term "anti-hepatitis C virally effective amount" of a compound of the invention, as used herein, means a sufficient amount of the compound so as to decrease the viral load in a subject, thus decreasing said subject's chronic HCV

symptoms. As well understood in the medical arts an anti-hepatitis C virally effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.

5 Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, 10 treatment should cease. The subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician 15 within the scope of sound medical judgment. The specific anti-HCV virally effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of 20 administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

25 The total daily dose of the compounds of this invention administered to a subject in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to 30 about 1000 mg of the compound(s) of this invention per day in single or multiple doses.

Pharmaceutical Compositions

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.

5 As used herein, the term "pharmaceutically acceptable carrier or excipient" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its
10 derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium
15 hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the
20 composition, according to the judgment of the formulator.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by
25 injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes
30 subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents,

5 solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides
10 inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

15 Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are
20 water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

25

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

30

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its

rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in

5 biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible
10 with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a

15 suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills,

20 powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose,
25 and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin
30 and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

5 The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally,
10 in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions,
15 sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

20 The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

25 Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

30 Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be

controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

Antiviral Activity

5

"An effective amount" refers to an amount of a compound which confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described

10 above may range from about 0.1 mg/Kg to about 500 mg/Kg, alternatively from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.

15 Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

20

The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident

25 to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.

Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock,

30 *Comprehensive Organic Transformations*, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995), and subsequent editions thereof.

According to the methods of treatment of the present invention, viral infections are treated or prevented in a subject such as a human or lower mammal by administering to the subject a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result. The term "anti-hepatitis C virally effective amount" of a compound of the invention, as used herein, means a sufficient amount of the compound so as to decrease the viral load in a subject, thus decreasing said subject's chronic HCV symptoms. As well understood in the medical arts an anti-hepatitis C virally effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.

Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. The subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

20

It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific anti-HCV virally effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one with ordinary skill in the art. All publications, patents, published patent applications, pending U.S. patent


applications, and other references mentioned herein are hereby incorporated by reference in their entirety.

5

Abbreviations

Abbreviations which have been used in the descriptions of the schemes and 10 the examples that follow are:

ACN for acetonitrile;
BME for 2-mercaptopropanoic acid;
BOP for benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate;
15 COD for cyclooctadiene;
DAST for diethylaminosulfur trifluoride;
DABCYL for 6-(N-4'-carboxy-4-(dimethylamino)azobenzene)- aminohexyl-1-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite;
DCM for dichloromethane;
20 DIAD for diisopropyl azodicarboxylate;
DIBAL-H for diisobutylaluminum hydride;
DIEA for diisopropyl ethylamine;
DMAP for N,N-dimethylaminopyridine;
DME for ethylene glycol dimethyl ether;
25 DMEM for Dulbecco's Modified Eagles Media;
DMF for N,N-dimethyl formamide;
DMSO for dimethylsulfoxide;



EDANS for 5-(2-Amino-ethylamino)-naphthalene-1-sulfonic acid;

EDCI or EDC for 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
EtOAc for ethyl acetate;
HATU for O (7-Azabenzotriazole-1-yl)-N,N,N',N' – tetramethyluronium
hexafluorophosphate;

5 Hoveyda's Cat. for Dichloro(o-isopropoxyphenyl)methylene)
(tricyclohexylphosphine)ruthenium(II);
KHMDS is potassium bis(trimethylsilyl) amide;
Ms for mesyl;
NMM for N-4-methylmorpholine;

10 PyBrOP for Bromo-tri-pyridino-phosphonium hexafluorophosphate;
Ph for phenyl;
RCM for ring-closing metathesis;
RT for reverse transcription;
RT-PCR for reverse transcription-polymerase chain reaction;


15 TEA for triethyl amine;
TFA for trifluoroacetic acid;
THF for tetrahydrofuran;
TLC for thin layer chromatography;
TPP or PPh₃ for triphenylphosphine;

20 tBOC or Boc for tert-butyloxy carbonyl; and
Xantphos for 4,5-Bis-diphenylphosphanyl-9,9-dimethyl-9H-xanthene.

Synthetic Methods


25 The compounds and processes of the present invention will be better
understood in connection with the following synthetic schemes which illustrate the
methods by which the compounds of the invention may be prepared.

Scheme 1



Boc-alkenylhydrazine of formula (1-3) can be prepared with bromo-alkenes of formula (1-1), wherein j is as previously defined and Boc-hydrazine (1-2) in the presence of tetrabutylammonium iodide in acetonitrile and DMSO. The corresponding acid chloride of formula (1-4) can be prepared by treating compound of formula (1-3) with phosgene in DCM.

Scheme 2




10

Aza-peptide mesylate macrocycle of formula (2-4), wherein A, B, G, M, Q, and j are as previously defined, can be formed primarily by peptide coupling conditions well known in the art. First, Boc-hydroxyproline ethyl ester derivative of formula (2-1) undergoes Boc-cleavage to yield the deprotected hydrochloride followed by addition of the Boc-aza-peptide acid chloride of formula (1-4), where A, B, and j are as

previously defined, to yield compounds of the formula (2-2). Formation of tripeptide of formula (2-3) can be achieved through treatment with LiOH in THF/MeOH/H₂O to perform the hydrolysis of the ethyl ester and followed by coupling to P1 under standard amide bond forming conditions wherein G is as previously defined.


5 Subjecting tripeptide (2-3) to ring-closing metathesis conditions with a Ruthenium-based catalyst can afford the desired key intermediate (2-4) (for further details on ring closing metathesis see recent reviews: Grubbs et al., *Acc. Chem. Res.*, **1995**, *28*, 446; Shrock et al., *Tetrahedron* **1999**, *55*, 8141; Furstner, A. *Angew. Chem. Int. Ed.* **2000**, *39*, 3012; Trnka et al., *Acc. Chem. Res.* **2001**, *34*, 18; and 10 Hoveyda et al., *Chem. Eur. J.* **2001**, *7*, 945).

Scheme 3



15 Aza-peptide mesylate macrocycle of formula (3-1) can be formed via treatment of compounds of (2-4) with mesyl chloride.


Scheme 4



The compounds of the present invention can be prepared via the replacement of the mesylate moiety of formula (3-1) with nucleophilic P* moiety Q in the presence of a base such as Cs₂CO₃ in DMF to form compounds of formula (4-1), wherein A, B, G, Q, and j are as previously defined. Examples of Q include, but are not limited to, 5 triazoles, tetrazoles, imidazoles, benzimidizoles, benzotriazoles, pyrroles, and the like.

Compounds of formula (4-2), where A, B, G, M, Q, and j are as previously defined, can be synthesized via Mitsunobu conditions from the cyclic precursor of formula (2-4) and acidic alcohols or other acidic components which include, but are 10 not limited to, phosphoric mono- and diesters, carboxylic acids, phenols, imides, oximes, hydroxymates, heterocycles, thiols, thioamides, β -keto esters, and the like. For further details on the Mitsunobu reaction, see O. Mitsunobu, *Synthesis* 1981, 1-28; D. L. Hughes, *Org. React.* 29, 1-162 (1983); D. L. Hughes, *Organic Preparations and Procedures Int.* 28, 127-164 (1996); and J. A. Dodge, S. A. Jones, *Recent Res. 15 Dev. Org. Chem.* 1, 273-283 (1997).

Scheme 5




Examples of compounds of the present invention which can be made via

introduction of various P* moieties by mesylate replacement, include, but are not

5 limited to, compounds of formulae (5-1) – (5-4). For further details of the mesylate replacement method, please see commonly assigned patent applications U.S. Serial Nos. 10/360,947 (filed Feb. 7, 2003) and 10/365,854 (filed Feb. 13, 2003).

Scheme 6



Examples of compounds of the present invention which can be made from

cyclic precursor of formula (2-4) via introduction of various P* moieties by Mitsunobu

5 coupling, include, but are not limited to, compounds of formulae (6-1) – (6-3). For further details on suitable P* moieties and the introduction thereof, please see U.S. published patent application US2002/0037998; PCT published application WO 00/59929; and commonly assigned U.S. Serial Nos. 10/384,120 (filed March 7, 2003) and 10/418,759 (filed April 18, 2003).

10

Examples

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not to limit the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the

20 scope of the appended claims

Example 1. Compound of formula (1-4), wherein j=1.

A solution of 8-Bromo-oct-1-ene (26.2 mmol), Boc-hydrazine (2 eq.), and tetrabutyl-amonium iodide (~ 5 mg) in 10:1 ACN/DMSO is heated to 70°C overnight. The mixture is then cooled and the excess solvent *in vacuo* removed. The concentrated reaction mixture is then purified via silica gel column chromatography (15-20% EtOAc/Hexane) to yield a compound of formula (1-3), wherein j = 1, as a clear oil. Triphosgene in DCM (5 ml) is added at 0°C to a mixture of compound of formula (1-3) and DIEA (0.8ml) in DCM (20ml) and stirred 1.5 hours to yield the title compound *in situ* to be used in subsequent steps.

Example 2. Compound of formula I, wherein A = Boc, B = hydrogen, G =OEt, M = -O-, Q = hydrogen, and j = n = s = 1.

Step 2a. Compound of formula (2-2), wherein A = Boc, B = hydrogen, T = OEt, and j = 1.

The mixture of the title compound of Example 1 is added to a pre-stirred solution of cis-L-hydroxyproline ethyl ester hydrochloride and DIEA (1.2 ml) in DCM (10ml). This mixture is then stirred overnight and then monitored for product formation via TLC. Once the reaction is deemed to be complete, the reaction mixture is then evaporated *in vacuo* to dryness and subsequently diluted in EtOAc. This mixture is then washed with water, NaHCO₃, and brine before the organic phase is dried over anhydrous sodium sulfate. The dried organic phase is then concentrated *in vacuo* and subsequently purified via silica gel column chromatography, eluting with 30-40% EtOAc/Hexane to yield the title compound as a white powder.

Step 2b. Compound of formula (2-3), wherein A = Boc, B = hydrogen, T = OH, and j = 1.

To a mixture of the compound from Step 2a (0.472 mmol) in THF/MeOH/H₂O (4:2:1) (10.5 ml) is added LiOH•H₂O (40mg). After stirring the resulting mixture at room temperature for 30 min., the reaction is concentrated *in vacuo* to remove excess MeOH and THF. The concentrate reaction mixture is then acidified to pH 4 with citric acid and

subsequently extracted 3 times with EtOAc. The combined organic extracts are then washed with brine, dried over anhydrous MgSO₄, and concentrated *in vacuo* to yield a white foam.

5 Step 2c. Compound of formula (2-3), wherein A = Boc, B = hydrogen, G = OEt, and j = 1.


A mixture of the compound formed in Step 2b, P1 (1 eq), HATU (1 eq), and NMM (3 eq) in DMF is stirred at room temperature for 45 min.. The reaction mixture is then diluted with water and extracted 3 times with EtOAc. The combined organic extract is washed with NaHCO₃ and brine, dried over anhydrous MgSO₄, and concentrated *in vacuo* to afford a light yellow residue. This resulting residue is purified by silica gel column chromatography eluting with 60% EtOAc/Hexane to yield the tripeptide as 10 a white foam.

15 Step 2d. Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-O-$, and Q = hydrogen, and j = n = s = 1.


A solution of the linear tripeptide formed in step c in dry DCM is deoxygenated by bubbling N₂. Hoveyda's 1st generation catalyst (5 mol% eq.) is then added as solid. The reaction is refluxed under N₂ atmosphere 12 hours. The solvent is evaporated and the residue is purified by silica 20 gel flash chromatography using different ratios of hexanes:EtOAc as elution phase (9:1 \rightarrow 5:1 \rightarrow 3:1 \rightarrow 1:1 \rightarrow 1:2 \rightarrow 1:5). The cyclic peptide precursor title compound is isolated as a white powder after removal of the elution solvents.

25 Example 3. Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-O-$, Q = $-S(O)_2CH_3$, and j = n = s = 1.


To a solution of the macrocyclic peptide precursor of Example 2 and DIEA in DCM, mesylate chloride (0.1 ml) is added slowly at 0 °C where the reaction is kept for 3 h. The reaction mixture is then diluted with EtOAc, washed with 5% 30 citric acid, water, 1M NaHCO₃ and brine 2x10 ml, respectively. The organic phase is then dried over anhydrous Na₂SO₄ and concentrated *in vacuo*, yielding the title compound mesylate with no need to for further purification for use in subsequent steps.

Example 4. Compound of formula I, wherein A = Boc, B = hydrogen, G =OEt, M =

To a cooled mixture of macrocyclic precursor of Example 2, 3-(thiophen-2-yl)-5-1H-quinoxalin-2-one (1.1 equiv.), and triphenylphosphine (2 equiv.) in THF is added DIAD (2 equiv.) dropwise at 0°C. The resulting mixture is held at 0°C for 15 min. before being warmed to room temperature. After 18 hours, the mixture is concentrated under vacuum and the residue is purified by chromatography eluting with 60% ethyl acetate-hexane to give the title compound.

Example 5. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M =

A solution of compound the compound of Example 4 and lithium hydroxide (10 equiv.) in THF/MeOH/H₂O (2:1:0.5) is stirred at room temperature for 20 hours. The excess solvents are evaporated *in vacuo*, the resulting residue is diluted with water, followed by acidification to pH ~5. The mixture is extracted 2 times with ethyl acetate. The combined organic extracts are washed once with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give an oily residue, which is purified by column chromatography.

Example 6. Compound of formula I, wherein A = Boc, B = hydrogen, G =OEt, M is

absent, Q = , and j = n = s = 1.

The title compound is prepared by dissolving compound of Example 3 and 4,5-diphenyltriazole in of DMF, adding cesium carbonate, and stirring the resulting mixture at 70°C for 12 hours. The reaction mixture is then extracted with EtOAc and washed with 1M sodium bicarbonate (2x30ml) and water

(2x30ml). The resulting organic solution was concentrated *in vacuo* to yield the title compound.

Additional compounds of the present invention that may be prepared via

5 methods described in U.S. published patent application US2002/0037998; PCT published application WO 00/59929; and commonly assigned U.S. Serial Nos. 10/384,120 (filed March 7, 2003), 10/418,759 (filed April 18, 2003), 10/360,947 (filed Feb. 7, 2003) and 10/365,854 (filed Feb. 13, 2003).

10 Example 7. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4,5-di-thiophenyltriazol-2-yl, and j = n = s = 1.

Example 8. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(thiophen-3-yl)-5-(p-methoxyphenyl)triazol-2-yl, and j = n = s = 1.

15 Example 9. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(n-butyl)-5-phenyl triazol-2-yl, and j = n = s = 1.

20 Example 10. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3-methoxyphenyl)tetrazolyl, and j = n = s = 1.

Example 11. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(4-pyridyl)tetrazolyl, and j = n = s = 1.

25 Example 12. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3,4-dichlorophenyl)tetrazolyl, and j = n = s = 1.

Example 13. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3-bromo-4-methoxy-phenyl)tetrazolyl, and j = n = s = 1.

30 Example 14. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(4-fluoro-phenyl)-6-phenyl-1H-pyridazin-3-on-2-yl, and j = n = s = 1.

Example 15. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 6-phenyl-5-piperidin-1-yl-1H-pyridazin-3-on-2-yl, and j = n = s = 1.

5 Example 16. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-phenyl-quinolin-4-yl, and j = n = s = 1.

Example 17. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-thiazolyl-quinolin-4-yl, and j = n = s = 1.

10 Example 18. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-thiophenyl-quinolin-4-yl, and j = n = s = 1.

Example 19. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-(thiophen-2-yl)-1H-quinoxalin-2-yl, and j = n = s = 1.

15 Example 20. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 6-Methoxy-3-(thiophen-2-yl)-1H-quinoxalin-2-yl, and j = n = s = 1.

20 Example 21. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-[2-(thiophen-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1.

25 Example 22. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 6-Methoxy-3-[2-(thiophen-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1.

Example 23. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-[2-(pyridin-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1.

30 Example 24. Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-methoxy-3-[2-(pyridin-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1.

Example 25. NS3/NS4a Protease Enzyme Assay

HCV protease activity and inhibition is assayed using an internally quenched fluorogenic substrate. A DABCYL and an EDANS group are attached to opposite ends of a short peptide. Quenching of the EDANS fluorescence by the DABCYL group is relieved upon proteolytic cleavage. Fluorescence was measured with a Molecular Devices Fluoromax (or equivalent) using an excitation wavelength of 355 nm and an emission wavelength of 485 nm.

The assay is run in Corning white half-area 96-well plates (VWR 29444-312 [Corning 3693]) with full-length NS3 HCV protease 1b tethered with NS4A cofactor (final enzyme concentration 1 to 15 nM). The assay buffer is complemented with 10 μ M NS4A cofactor Pep 4A (Anaspec 25336 or in-house, MW 1424.8). RET S1 (Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-[COO]Ala-Ser-Lys-(DABCYL)-NH₂, AnaSpec 22991, MW 1548.6) is used as the fluorogenic peptide substrate. The assay buffer contained 50 mM Hepes at pH 7.5, 30 mM NaCl and 10 mM BME. The enzyme reaction is followed over a 30 minutes time course at room temperature in the absence and presence of inhibitors.

The peptide inhibitors HCV Inh 1 (Anaspec 25345, MW 796.8) Ac-Asp-Glu-Met-Glu-Glu-Cys-OH, [-20°C] and HCV Inh 2 (Anaspec 25346, MW 913.1) Ac-Asp-Glu-Dif-Cha-Cys-OH, were used as reference compounds.

IC₅₀ values were calculated using XLFit in ActivityBase (IDBS) using equation 205: $y=A+((B-A)/(1+((C/x)^D)))$.

25 Example 26. Cell-Based Replicon Assay

Quantification of HCV replicon RNA in cell lines (HCV Cell Based Assay)

Cell lines, including Huh-11-7 or Huh 9-13, harboring HCV replicons (Lohmann, et al Science 285:110-113, 1999) are seeded at 5x10³ cells/well in 96 well plates and fed media containing DMEM (high glucose), 10% fetal calf serum, penicillin-streptomycin and non-essential amino acids. Cells are incubated in a 5% CO₂ incubator at 37 °C. At the end of the incubation period, total RNA is extracted and purified from cells using Qiagen Rneasy 96 Kit (Catalog No. 74182). To amplify the HCV RNA so that sufficient material

can be detected by an HCV specific probe (below), primers specific for HCV (below) mediate both the reverse transcription of the HCV RNA and the amplification of the cDNA by polymerase chain reaction (PCR) using the TaqMan One-Step RT-PCR Master Mix Kit (Applied Biosystems catalog no. 5 4309169). The nucleotide sequences of the RT-PCR primers, which are located in the NS5B region of the HCV genome, are the following:

- HCV Forward primer "RBNS5bfor"
 - ◆ 5'GCTGCGGCCTGTCGAGCT:
- HCV Reverse primer "RBNS5Brev":
 - ◆ 5'CAAGGTCGTCTCCGCATAC

10 Detection of the RT-PCR product was accomplished using the Applied Biosystems (ABI) Prism 7700 Sequence Detection System (SDS) that detects the fluorescence that is emitted when the probe, which is labeled with a fluorescence reporter dye and a quencher dye, is processed during the PCR 15 reaction. The increase in the amount of fluorescence is measured during each cycle of PCR and reflects the increasing amount of RT-PCR product. Specifically, quantification is based on the threshold cycle, where the 20 amplification plot crosses a defined fluorescence threshold. Comparison of the threshold cycles of the sample with a known standard provides a highly sensitive measure of relative template concentration in different samples (ABI User Bulletin #2 December 11, 1997). The data is analyzed using the ABI SDS program version 1.7. The relative template concentration can be converted to RNA copy numbers by employing a standard curve of HCV RNA 25 standards with known copy number (ABI User Bulletin #2 December 11, 1997).

The RT-PCR product was detected using the following labeled probe:

- 5' FAM-CGAAGCTCCAGGACTGCACGATGCT-TAMRA
- FAM= Fluorescence reporter dye.
- TAMRA:=Quencher dye.

30 The RT reaction is performed at 48 °C for 30 minutes followed by PCR. Thermal cycler parameters used for the PCR reaction on the ABI Prism 7700

Sequence Detection System were: one cycle at 95 °C, 10 minutes followed by 35 cycles each of which included one incubation at 95 °C for 15 seconds and a second incubation for 60 °C for 1 minute.

5 To normalize the data to an internal control molecule within the cellular RNA, RT-PCR is performed on the cellular messenger RNA glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The GAPDH copy number is very stable in the cell lines used. GAPDH RT-PCR is performed on the same exact RNA sample from which the HCV copy number is determined. The GAPDH primers and probes, as well as the standards with which to determine copy number, are contained in the ABI Pre-Developed TaqMan Assay Kit (catalog no. 4310884E). The ratio of HCV/GAPDH RNA is used to calculate the activity of compounds evaluated for inhibition of HCV RNA replication.

10

15 **Activity of compounds as inhibitors of HCV replication (Cell based Assay) in replicon containing Huh-7 cell lines**

The effect of a specific anti-viral compound on HCV replicon RNA levels in Huh-11-7 or 9-13 cells was determined by comparing the amount of HCV RNA normalized to GAPDH (e.g. the ratio of HCV/GAPDH) in the cells exposed to compound versus cells exposed to the 0% inhibition and the 100% inhibition controls. Specifically, cells were seeded at 5×10^3 cells/well in a 96 well plate and were incubated either with: 1) media containing 1% DMSO (0% inhibition control), 2) 100 international units, IU/ml Interferon-alpha 2b in media/1%DMSO or 3) media/1%DMSO containing a fixed concentration of compound. 96 well plates as described above were then incubated at 37 °C for 3 days (primary screening assay) or 4 days (IC50 determination). Percent inhibition was defined as:

20

25

$$\text{% Inhibition} = [100 - ((S - C2) / (C1 - C2))] \times 100$$

30

- where
- S= the ratio of HCV RNA copy number/GAPDH RNA copy number in the sample;

- C1= the ratio of HCV RNA copy number/GAPDH RNA copy number in the 0% inhibition control (media/1%DMSO); and
- C2= the ratio of HCV RNA copy number/GAPDH RNA copy number in the 100% inhibition control (100 IU/ml Interferon-alpha 2b).


5

The dose-response curve of the inhibitor was generated by adding compound in serial, three-fold dilutions over three logs to wells starting with the highest concentration of a specific compound at 10uM and ending with the lowest concentration of 0.01uM. Further dilution series (1uM to 0.001uM for example) was performed if the IC50 value was not in the linear range of the curve. IC50 was determined based on the IDBS Activity Base program using Microsoft Excel "XL Fit" in which A=100% inhibition value (100IU/ml Interferon-alpha 2b), B= 0% inhibition control value (media/1%DMSO) and C= midpoint of the curve as defined as $C=(B-A/2)+A$. A, B and C values are expressed as the ratio of HCV RNA/GAPDH RNA as determined for each sample in each well of a 96 well plate as described above. For each plate the average of 4 wells were used to define the 100% and 0% inhibition values.

Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

WHAT IS CLAIMED:

1. A compound of Formula I:



(I)

5

wherein

A is selected from:

(a) hydrogen;

(b) -(C=O)-O-R₁, where R₁ is selected from:

10

1. hydrogen,
2. C₁-C₆ alkyl,
3. C₃-C₁₂ cycloalkyl,
4. substituted C₃-C₁₂ cycloalkyl,
5. aryl,
6. substituted aryl,
7. heteroaryl,
8. substituted heteroaryl,
9. heterocycloalkyl,
10. substituted heterocycloalkyl, or

15

11. -C₁-C₆ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

20

(c) -(C=O)-R₂, where R₂ is selected from:

25

1. -R₁, where R₁ is as previously defined,
2. alkylamino,

3. dialkyl amino,

4. arylamino, or

5. diarylamino;

5 (d) $-\text{C}(=\text{O})-\text{NH}-\text{R}_2$, where R_2 is as previously defined;

(e) $-\text{C}(=\text{S})-\text{NH}-\text{R}_2$, where R_2 is as previously defined;

(f) $-\text{S}(\text{O})_2-\text{R}_2$, where R_2 is as previously defined;

B is hydrogen or C_1-C_6 alkyl;

G is

(a) $-\text{OH}$;

10 (b) $-\text{O}-(\text{C}_1-\text{C}_{12}$ alkyl);

(c) $-\text{NH}-\text{R}_2$, where R_2 is as previously defined;

(d) $-\text{NHS}(\text{O})_2-\text{R}_1$, where R_1 as previously defined;

(e) $-(\text{C}=\text{O})-\text{R}_2$, where R_2 as previously defined;

(f) $-(\text{C}=\text{O})-\text{O}-\text{R}_1$, where R_1 as previously defined; or

15 (g) $-(\text{C}=\text{O})-\text{NH}-\text{R}_2$, where R_2 as previously defined;

M is absent or selected from:

(a) $-\text{O}-$;

(b) $-\text{S}-$;

(c) $-\text{NH}-$; or

20 (d) $-\text{NR}_1-$, wherein R_1 is previously defined;

Q is selected from:

(a) aryl;

(b) substituted aryl;

(c) heteroaryl;

25 (d) substituted heteroaryl;


(e) heterocycloalkyl; or

(f) substituted heterocycloalkyl;

$j = 0, 1, 2, 3$, or 4 ;

$n = 0, 1$, or 2 ; and

30 $s = 0, 1$, or 2 .



2. A compound of formula I, wherein M is absent and Q is


wherein X and Y are each independently selected from:

- 5 a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 10 b) $-C_2-C_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 15 c) $-C_2-C_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- 15 e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

20 or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;


25 3. A compound of formula I, wherein M is absent and Q is
wherein Y is selected from:

- 30 a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;



- b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 5 c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- 10 e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

15




4. A compound of formula I, wherein M is absent and Q is

wherein X, Y, and Z are each independently selected from:

- a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 20 b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 25 d) aryl;
- e) substituted aryl;

- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

5 or in the alternative, X and Y or Y and Z are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;




10 5. A compound of formula I, wherein M is absent and Q is

wherein W, X, Y, and Z are each independently selected from:

- a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-C_2-C_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-C_2-C_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

25 or in the alternative, W and X, X and Y, or Y and Z are taken together with the carbons to which they are attached to for a cyclic moiety selected from:

aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;




6. A compound of formula I, wherein M is absent and Q is

5 wherein X, Y, and Z are each independently selected from:

- a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, Y and Z are taken together with the carbons to which

25 they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;



7. A compound of formula I, wherein M is $-\text{O}-$ and Q is


wherein

L is M, where M is as previously defined;

X, Y, and Z are each independently selected from:

- 5 a) $-C_1-C_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- b) $-C_2-C_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 10 c) $-C_2-C_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
- 15 d) aryl;
- e) substituted aryl;
- f) heteroaryl;
- g) substituted heteroaryl;
- 20 h) heterocycloalkyl; or
- i) substituted heterocycloalkyl;

or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;



25 8. A compound of formula I, wherein M is $-O-$ and Q is

wherein

L is M, where M is as previously defined;

30 X, Y, and Z are each independently selected from:

a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

5 b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

10 c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

15 d) aryl;

e) substituted aryl;


f) heteroaryl;

g) substituted heteroaryl;

h) heterocycloalkyl; or

i) substituted heterocycloalkyl;

or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl; or



9. A compound of formula I, wherein M is $-\text{O}-$ and Q is

25 wherein

L is M, where M is as previously defined;

X, Y, and Z are each independently selected from:

a) $-\text{C}_1\text{--C}_6$ alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

30

5 b) $-\text{C}_2\text{--C}_6$ alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

10 c) $-\text{C}_2\text{--C}_6$ alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

15 d) aryl;

 e) substituted aryl;

 f) heteroaryl;

 g) substituted heteroaryl;

 h) heterocycloalkyl; or

 i) substituted heterocycloalkyl;

or in the alternative, X and Y are taken together with the carbons to which they are attached to for a cyclic moiety selected from: aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl.

20 10. A compound according to claim 1 represented by formula I selected from:
Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-\text{O}-$, Q = hydrogen, and $j = n = s = 1$;

25 Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-\text{O}-$, Q = $-\text{S}(\text{O})_2\text{CH}_3$, and $j = n = s = 1$;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M = $-\text{O}-$, Q = 2-thiophenyl-quinolin-4-yl, and $j = n = s = 1$;

30 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = $-\text{O}-$, Q = 2-thiophenyl-quinolin-4-yl, and $j = n = s = 1$;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OEt, M is absent, Q = 4,5-diphenyltriazol-2-yl, and j = n = s = 1;

5 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4,5-di-thiophenyltriazol-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(thiophen-3-yl)-5-(p-methoxyphenyl)triazol-2-yl, and j = n = s = 1;

10 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(n-butyl)-5-phenyltriazol-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3-methoxyphenyl)tetrazol-2-yl, and j = n = s = 1;

15 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(4-pyridyl)tetrazol-2-yl, and j = n = s = 1;

20 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3,4-dichlorophenyl)tetrazol-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 5-(3-bromo-4-methoxy-phenyl)tetrazol-2-yl, and j = n = s = 1;

25 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 4-(4-fluoro-phenyl)-6-phenyl-1H-pyridazin-3-on-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M is absent, Q = 6-phenyl-5-piperidin-1-yl-1H-pyridazin-3-on-2-yl, and j = n = s = 1;

30 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-phenyl-quinolin-4-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-thiazolyl-quinolin-4-yl, and j = n = s = 1;

5 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-2-thiophenyl-quinolin-4-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-(thiophen-2-yl)-1H-quinoxalin-2-yl, and j = n = s = 1;

10 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 6-Methoxy-3-(thiophen-2-yl)-1H-quinoxalin-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-Methoxy-3-[2-(thiophen-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1;

15 Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 6-Methoxy-3-[2-(thiophen-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1;

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 20 7-Methoxy-3-[2-(pyridin-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1; or

Compound of formula I, wherein A = Boc, B = hydrogen, G = OH, M = -O-, Q = 7-methoxy-3-[2-(pyridin-2-yl)vinyl]-1H-quinoxalin-2-yl, and j = n = s = 1.

25 11. A pharmaceutical composition comprising an anti-hepatitis C virally effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, ester, or prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient.

30 12. A method of treating a hepatitis C viral infection in a mammal, comprising administering to the mammal an anti-hepatitis C virally effective amount of a pharmaceutical composition according to claim 11.

13. A method of inhibiting the replication of hepatitis C virus, the method comprising supplying a hepatitis C viral NS3 protease inhibitory amount of the pharmaceutical composition of claim 11.

5 14. The method of claim 13 further comprising administering concurrently an additional anti-hepatitis C virus agent.


15. The method of claim 14, wherein said additional anti-hepatitis C virus agent is selected from the group consisting of: α -interferon, β -interferon, ribavarin, and adamantine.

10 adamantine.


16. The method of claim 14, wherein said additional anti-hepatitis C virus agent is an inhibitor of another target in the hepatitis C virus life cycle, which is selected from the group consisting of: helicase, polymerase, metalloprotease, and IRES.

15

17. A process of making compounds of formula I:




wherein A, B, G, M, Q, j, n, and s are as defined in claim 1, comprising the steps of:




(a) reacting a compound of formula (A):

20 and j is as defined in claim 1 with a hydroxyproline ethyl ester derivative of
formula (B): in the presence of a base to form a compound of formula (C):




wherein A, B, and j are as defined in claim 1 and T is selected from OH, OMe, or OEt;

(b) reacting a compound of formula B with a compound of formula (D):



, wherein G is as defined in claim 1, under standard amide formation conditions to form a compound of formula (E):



, wherein A, B, G, M, Q, and j are as defined in claim 1; and

(c) reacting compound of formula E with a Ruthenium-based catalyst.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/015802

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K5/078 A61K38/05 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/59929 A (BOEHRINGER INGELHEIM CA LTD ; GOUDREAU NATHALIE (CA); GHIRO ELISE (CA)) 12 October 2000 (2000-10-12) cited in the application the whole document	1-17
Y	WEINSTEIN B: "CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES AND PROTEINS, PASSAGE" CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES, AND PROTEINS, XX, XX, vol. 7, 1983, pages 266-357, XP002032461 See particularly pages 292-295 abstract	1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the International search

1 November 2004

Date of mailing of the International search report

18/11/2004

Name and mailing address of the ISA
European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Fax. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/015802

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 00/09543 A (BOEHRINGER INGELHEIM CA LTD ; GOUDREAU NATHALIE (CA); GHIRO ELISE (CA)) 24 February 2000 (2000-02-24) cited in the application The whole document; see particularly page 10, line 23 to page 11, line 9 -----</p>	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/015802

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 12-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/015802

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0059929	A 12-10-2000	AT 277945 T		15-10-2004
		AU 3548000 A		23-10-2000
		BG 105970 A		31-05-2002
		BR 0009599 A		15-01-2002
		WO 0059929 A1		12-10-2000
		CA 2367127 A1		12-10-2000
		CN 1346365 T		24-04-2002
		CZ 20013467 A3		12-06-2002
		EE 200100516 A		16-12-2002
		EP 1169339 A1		09-01-2002
		EP 1437362 A1		14-07-2004
		HR 20010720 A1		31-12-2002
		HU 0300121 A2		28-06-2003
		ID 30459 A		06-12-2001
		JP 2002542160 T		10-12-2002
		NO 20014857 A		31-10-2001
		NZ 515286 A		27-02-2004
		PL 350855 A1		10-02-2003
		SK 14072001 A3		05-03-2002
		TR 200102878 T2		21-01-2002
		US 2004002448 A1		01-01-2004
		US 6608027 B1		19-08-2003
WO 0009543	A 24-02-2000	AU 769738 B2		05-02-2004
		AU 5273199 A		06-03-2000
		BG 105232 A		30-11-2001
		BR 9913646 A		05-06-2001
		CA 2338946 A1		24-02-2000
		CA 2445938 A1		24-02-2000
		WO 0009543 A2		24-02-2000
		CN 1323316 T		21-11-2001
		CZ 20010516 A3		15-08-2001
		EA 3906 B1		30-10-2003
		EE 200100081 A		15-08-2002
		EP 1105413 A2		13-06-2001
		HR 20010102 A1		28-02-2002
		HU 0105144 A2		29-04-2002
		ID 27839 A		26-04-2001
		JP 2002522554 T		23-07-2002
		NO 20010683 A		02-04-2001
		NZ 510396 A		27-02-2004
		PL 346626 A1		25-02-2002
		SK 2062001 A3		08-10-2001
		TR 200100432 T2		21-09-2001
		TR 200200129 T2		21-06-2002
		US 6534523 B1		18-03-2003
		US 6323180 B1		27-11-2001
		US 6268207 B1		31-07-2001
		US 6329379 B1		11-12-2001
		US 6329417 B1		11-12-2001
		US 2002016442 A1		07-02-2002
		US 2002037998 A1		28-03-2002